MBIO (Mustang Bio) Forward Dividend Yield % : 0.00% (As of Apr. 26, 2025)

View and export this data going back to 2017. Start your Free Trial

What is Mustang Bio Forward Dividend Yield %?

As of today (2025-04-26), the Forward Annual Dividend Yield of Mustang Bio is 0.00%.

As of today (2025-04-26), the Trailing Annual Dividend Yield of Mustang Bio is 0.00%.

MBIO's Forward Dividend Yield % is not ranked ^*
in the Biotechnology industry.
Industry Median: 1.53
* Ranked among companies with meaningful Forward Dividend Yield % only.

Mustang Bio's Dividends per Share for the three months ended in Dec. 2024 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Competitive Comparison of Mustang Bio's Forward Dividend Yield %

For the Biotechnology subindustry, Mustang Bio's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mustang Bio's Forward Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mustang Bio's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Mustang Bio's Forward Dividend Yield % falls into.

Save Embed

;

Save Embed

;

Mustang Bio Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.

Mustang Bio (NAS:MBIO) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.

Mustang Bio Forward Dividend Yield % Related Terms

Thank you for viewing the detailed overview of Mustang Bio's Forward Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Mustang Bio Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mustang Bio Inc (NAS:MBIO) » Definitions » Forward Dividend Yield %

Comparable Companies

Traded in Other Exchanges

N/A

Address

95 Sawyer Road, Suite 110, Waltham, MA, USA, 02453

Website

https://www.mustangbio.com

Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.

Executives

Fortress Biotech, Inc.	10 percent owner	1111 KANE CONCOURSE, SUITE 301, BAY HARBOR ISLANDS FL 33154
Rosenwald Lindsay A Md	director	375 PARK AVE, NEW YORK NY 10152
Manuel Md Litchman	director, officer: President and CEO	2 GANSEVOORT STREET, 9TH FLOOR, NEW YORK NY 10017
Eliot M Lurier	officer: Interim CFO	C/O TENAX THERAPEUTICS, INC., ONE COPLEY PARKWAY, SUITE 490, MORRISVILLE NC 27560
Brian Achenbach	officer: SVP, Fin. & Corp. Controller	2 GANSEVOORT STREET, 9TH FLOOR, NEW YORK NY 10014
Neil Herskowitz	director	2109 BROADWAY, SUITE 206, NEW YORK NY 10023
Adam J. Chill	director	24 NEW ENGLAND EXECUTIVE PARK, SUITE 105, BURLINGTON MA 01803
Michael S Weiss	director	750 LEXINGTON AVE, NEW YORK NY 10022
Michael J Zelefsky	director
David J Horin	officer: Interim CFO	1270 AVENUE OF THE AMERICAS, 16TH FLOOR, NEW YORK NY 10020